Emergent BioSolutions Inc. (EBS)
收市後：
| 前收市價 | 3.4400 |
| 開市 | 3.4400 |
| 買盤 | 3.2100 x 3100 |
| 賣出價 | 3.3300 x 1800 |
| 今日波幅 | 3.2000 - 3.4700 |
| 52 週波幅 | 3.2000 - 21.8800 |
| 成交量 | |
| 平均成交量 | 2,374,854 |
| 市值 | 168.891M |
| Beta 值 (5 年，每月) | 0.88 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -11.3900 |
| 業績公佈日 | 2023年11月06日 - 2023年11月10日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 12.25 |
BenzingaFDA Approves First OTC Naloxone Nasal Spray For Opioid Overdose
The FDA has approved Emergent BioSolutions Inc's (NYSE: EBS) Narcan, 4 milligrams (mg) naloxone hydrochloride nasal spray for over-the-counter (OTC), nonprescription use – the first naloxone product approved for use without a prescription. Naloxone is a medication that rapidly reverses the effects of opioid overdose and is the standard treatment for opioid overdose. The move paves the way for the medication to reverse an opioid overdose to be sold directly to consumers in drug stores, convenienc
Insider MonkeyEmergent BioSolutions Inc. (NYSE:EBS) Q4 2022 Earnings Call Transcript
Emergent BioSolutions Inc. (NYSE:EBS) Q4 2022 Earnings Call Transcript February 27, 2023 Operator: Good day and thank you for standing by. Welcome to the Emergent BioSolutions Fourth Quarter and Full Year 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer […]
BenzingaMonkeypox Vaccine Maker Bavarian Nordic Bets $380M On Emergent Bio's Travel Vaccines
Bavarian Nordic A/S (OTC: BVNRY) has agreed to acquire two marketed travel vaccines, Vivotif for the prevention of typhoid fever and Vaxchora against cholera, from Emergent BioSolutions Inc (NYSE: EBS). The company will also acquire a Phase 3 vaccine candidate to prevent the Chikungunya virus. The deal consideration of $380 million includes $270 million in an upfront payment and up to $110 million in future conditional milestone payments. The acquisition also includes facilities and key personne
